Jan Thirkettle
Algemeen Directeur bij Transine Therapeutics Ltd.
Oorsprong van het eerstegraads netwerk van Jan Thirkettle
Entiteit | Type entiteit | Industrie | |
---|---|---|---|
Transine Therapeutics Ltd.
Transine Therapeutics Ltd. Pharmaceuticals: MajorHealth Technology Transine Therapeutics Ltd. is an RNA platform company based in Cambridge, UK. The British company is developing a novel class of therapeutic RNAs called SINEUPs, which can upregulate protein expression with a superior level of control and specificity across an unprecedented range of diseases and applications. The company's proprietary technology allows them to address diseases that have been beyond the reach of small molecules, conventional biologics, or gene therapies. The SINEUP platform boosts the expression of almost any chosen target protein by binding precisely to the mRNA that encodes it and enhancing its translation. This technology massively extends the druggable proteome and represents an entirely new mechanism of action, ideally suited to address currently hard-to-treat diseases. The company was founded in 2018 by Stefano Gustincich and Piero Carninci. Jan Thirkettle has been the CEO of the company since 2021.
8
| Holding Company | Pharmaceuticals: Major | 8 |
Grafiek van bedrijven verbonden in de tweede graad
Connectie in verschillende bedrijven
Bedrijven verbonden met Jan Thirkettle via zijn persoonlijke netwerk
Onderneming | Sector | Gelieerde personen | Hoofdpost |
---|---|---|---|
Catamaran Bio, Inc.
Catamaran Bio, Inc. Financial ConglomeratesFinance Catamaran Bio, Inc. provides investment services. The company is headquartered in Delaware. | Financial Conglomerates | Corporate Officer/Principal Director/Board Member | |
Takeda Ventures, Inc.
Takeda Ventures, Inc. Investment ManagersFinance Takeda Ventures Inc (Takeda Ventures) is a venture capital subsidiary of Takeda America Holdings Inc founded in 2001. The firm is headquartered in Palo Alto, California. | Investment Managers | Private Equity Investor Private Equity Investor | |
University of Birmingham | College/University | Undergraduate Degree Doctorate Degree | |
Cigna Behavioral Health, Inc.
Cigna Behavioral Health, Inc. Managed Health CareHealth Services Cigna Behavioral Health, Inc. provides healthcare services and plans. It manages behavioral health care benefits and employee assistance programs (EAPs) for health plan members nationwide. The firm's services include disability management programs for employees on short and long-term disability and referral services such as financial and legal services, childcare and eldercare. The company was founded in 1974 and is headquartered in Eden Prairie, MN. | Managed Health Care | Chief Tech/Sci/R&D Officer | |
Curve Therapeutics Ltd.
Curve Therapeutics Ltd. Miscellaneous Commercial ServicesCommercial Services Curve Therapeutics Ltd. operates as a drug-discovery company. It engages on the development of innovative technologies to address undruggable disease-modifying targets, with an in-house focus on cancer. The company was founded in 2019 and is headquartered in London, the United Kingdom. | Miscellaneous Commercial Services | Director/Board Member | |
Emendo Biotherapeutics, Inc.
Emendo Biotherapeutics, Inc. BiotechnologyHealth Technology Emendo Biotherapeutics, Inc. engages in the development of genome editing technology. It specializes in protein engineering, molecular biology, and gene editing systems. The company was founded by David Baram, Lior Izhar, and Rachel Diamant in 2015 and is headquartered in New York, NY. | Biotechnology | Director/Board Member | |
University of Oxford | College/University | Graduate Degree | |
Panakes Partners SGR SpA
Panakes Partners SGR SpA Investment ManagersFinance Panakes Partners Sgr SpA (Panakes Partners) is a venture capital firm founded in 2015 by Alessio Beverina, Fabrizio Landi and Diana Sareceni. The firm is headquartered in Milan, Italy. | Investment Managers | Private Equity Investor | |
University of Cambridge | College/University | Graduate Degree | |
Obsidian Therapeutics, Inc.
Obsidian Therapeutics, Inc. BiotechnologyHealth Technology Obsidian Therapeutics, Inc. develops cell and gene therapeutics that employ precise exogenous control of transgenes for improved safety and efficacy. The company was founded in 2016 and is headquartered in Cambridge, MA. | Biotechnology | Corporate Officer/Principal | |
Abintus Bio, Inc.
Abintus Bio, Inc. Miscellaneous Commercial ServicesCommercial Services Abintus Bio, Inc. operates as a preclinical stage gene therapy company. It provides immune cell reprogramming services. The company was founded by John Snyder, Nicholas A. Boyle, Douglas J. Jolly, Carlos Ibañez, Derek Ostertag, and Cory Bentley and is headquartered in Encinitas, CA. | Miscellaneous Commercial Services | Corporate Officer/Principal | |
Caldan Therapeutics Ltd.
Caldan Therapeutics Ltd. Miscellaneous Commercial ServicesCommercial Services Caldan Therapeutics Ltd. provides novel therapeutics targeting free fatty acid. It focuses on developing drugs in order to deliver anti-diabetic effects in multiple tissues and organs. The company was founded by Graeme Milligan and Trond Ulven and is headquartered in Edinburgh, the United Kingdom. | Miscellaneous Commercial Services | Director/Board Member | |
BIOMX INC. | Biotechnology | Corporate Officer/Principal | |
Touchstone Innovations Investment Management Ltd.
Touchstone Innovations Investment Management Ltd. Investment ManagersFinance Touchstone Innovations Investment Management Ltd. is a Venture Capital firm, a subsidiary of Touchstone Innovations Ltd. founded in 1986. Touchstone Innovations Investment Management Ltd. is headquartered in London. | Investment Managers | Corporate Officer/Principal | |
Sofinnova Partners SAS
Sofinnova Partners SAS Investment ManagersFinance Sofinnova Partners SA (Sofinnova) is an independent venture capital firm established in 1972 and headquartered in Paris, France. Originally known as Sofinnova, the first venture capital firm created in France, the firm created a U.S. subsidiary in San Francisco in 1976. In 1997, both firms were bought out by their management teams, which become the majority shareholders of the new companies, Sofinnova Partners in Paris and Sofinnova Ventures in San Francisco. | Investment Managers | Corporate Officer/Principal | |
Integra Therapeutics SL
Integra Therapeutics SL Miscellaneous Commercial ServicesCommercial Services Integra Therapeutics SL is a Spanish Barcelona-based company founded in 2020 by Marc Güell and Avencia Sánchez-Mejías, with Avencia Sánchez-Mejías serving as the CEO since then. The company is focused on engineering the next-generation of gene writing tools to cure genetic and oncological diseases with high unmet medical need. Integra Therapeutics is committed to creating new gene writing tools that improve the scope, efficiency, and safety of advanced therapies. | Miscellaneous Commercial Services | Director/Board Member | |
University of Wisconsin | College/University | Masters Business Admin | |
Wesleyan University | College/University | Graduate Degree | |
Leucid Bio Ltd.
Leucid Bio Ltd. Miscellaneous Commercial ServicesCommercial Services Leucid Bio Ltd. is a clinical-stage biotechnology company based in London, UK. The British company develops novel, lateral car cell therapies for the treatment of refractory cancers, with a focus on developing next-generation cell therapies for the benefit of individuals with hard-to-treat solid tumors. The company's operations are based at Guys Hospital, enabling them to maintain a patient-centric focus. Leucid's goal is to develop CAR-T therapies with more durable responses, improving treatment outcomes and saving the lives of patients with refractory cancers. Leucid was established to translate 20 years of Kings College research in the CAR-T field and is led by a highly experienced management team, including scientific founder John Maher. Filippo Joseph Petti has been the CEO of the company since 2023. | Miscellaneous Commercial Services | Director/Board Member | |
The University of Edinburgh | College/University | Doctorate Degree | |
Lunac Therapeutics Ltd.
Lunac Therapeutics Ltd. Pharmaceuticals: MajorHealth Technology Lunac Therapeutics Ltd. engages in the identification and development of anticoagulants. The company was founded by Helen Philippou and Richard Foster on April 18, 2018 and is headquartered in Leeds, the United Kingdom. | Pharmaceuticals: Major | Director/Board Member | |
Alan Boyd Consultants Ltd. | Chief Executive Officer | ||
Celentyx Ltd.
Celentyx Ltd. BiotechnologyHealth Technology Celentyx Ltd. provides research and development on human immune disease. The firm's services include rapid analysis screening of drug action on physiological and pathological human immune tissues and cells. It provides services by disease, cell type, assay through its ImmuKnowlogy platform technology. The company was founded by Nicholas Mark Barnes and John Gordon in 2004 and is headquartered in Birmingham, the United Kingdom. | Biotechnology | Director/Board Member | |
The Royal College of Physicians | College/University | Corporate Officer/Principal | |
Spark Therapeutics Ireland Ltd.
Spark Therapeutics Ireland Ltd. Pharmaceuticals: MajorHealth Technology Spark Therapeutics Ireland Ltd. develops new gene medicines to treat autosomal dominant genetic diseases. Its product RhoNova, is designed for the treatment of patients with rhodopsin linked autosomal dominant retinitis pigmentosa, a debilitating, progressive form of inherited blindness resulting from a diverse array of mutations in the RHO gene. The company was founded by Jane G. Farrar, Paul Kenna, and Gearóid Tuohy and is headquartered in Dublin, Ireland. | Pharmaceuticals: Major | Director/Board Member | |
CLINIGEN GROUP PLC | Miscellaneous Commercial Services | Chief Tech/Sci/R&D Officer | |
Glaxo Group Research Ltd. | Corporate Officer/Principal | ||
Zeneca Pharmaceuticals
Zeneca Pharmaceuticals Pharmaceuticals: MajorHealth Technology Zeneca Pharmaceuticals manufactures medicines. | Pharmaceuticals: Major | Chief Tech/Sci/R&D Officer | |
Linear Diagnostics Ltd.
Linear Diagnostics Ltd. Medical SpecialtiesHealth Technology Linear Diagnostics Ltd. operates as a diagnostics company based on a novel technology that allows wide range of molecular diagnostics tests to be carried out using a simple optical system. It specializes in molecular diagnostics, novel technology and optical detection. The company was founded by Matt Hicks in 2011 and is headquartered in Birmingham, the United Kingdom. | Medical Specialties | Director/Board Member | |
Cell Guidance Systems Ltd.
Cell Guidance Systems Ltd. BiotechnologyHealth Technology Cell Guidance Systems Ltd. develops tools for stem cell treatments and medical research. Its products include microvesicles, cell culture media, PODS growth factors, matrigen softwell and SINEUP. The firm also offers karyotype analysis, custom medium production, NTA profiling service and PODS proteins services. The company was founded by Michael H. Jones in 2010 and is headquartered in Cambridge, the United Kingdom. | Biotechnology | Chief Executive Officer | |
AstraZeneca Canada, Inc.
AstraZeneca Canada, Inc. Pharmaceuticals: MajorHealth Technology AstraZeneca Canada, Inc. develops and manufactures pharmaceutical drug preparations. Its therapeutic areas include cardiovascular and metabolic disease, oncology, and respiratory, inflammation and autoimmunity. The firm also active in the infection, neuroscience and gastrointestinal disease areas. The company was founded in 1999 and is headquartered in Mississauga, Canada. | Pharmaceuticals: Major | Chief Tech/Sci/R&D Officer | |
High-Tech Gründerfonds Management GmbH
High-Tech Gründerfonds Management GmbH Investment ManagersFinance High-Tech Gründerfonds Management GmbH (HTGF) is a venture capital firm founded in 2005. The firm is headquartered in Bonn, Germany. | Investment Managers | Private Equity Investor | |
coramaze technologies GmbH
coramaze technologies GmbH Medical SpecialtiesHealth Technology coramaze technologies GmbH operates as a medical device company which develops valve repair system. It offers mitramaze a novel concept for transcatheter mitral valve repair intended for treatment of inoperable patients suffering from severe functional mitral regurgitation. The company was founded by Laura Figulla and Till Neumann in 2013 and is headquartered in Munich, Germany. | Medical Specialties | Director/Board Member | |
Wellington Partners GmbH
Wellington Partners GmbH Investment ManagersFinance Wellington Partners GmbH (Wellington Partners) is an independent venture capital firm founded in 1991 by Rolf Christof Dienst. The firm is headquartered in Munich, with offices in Zurich, London, and Palo Alto. | Investment Managers | Private Equity Investor | |
SV Health Investors LLP
SV Health Investors LLP Investment ManagersFinance SV Health Investors LLP (SV Health Investors) is a venture capital firm founded in 1994 by Peter McPartland. The firm is headquartered in London. | Investment Managers | Private Equity Investor | |
Loqus23 Therapeutics Ltd.
Loqus23 Therapeutics Ltd. BiotechnologyHealth Technology Loqus23 Therapeutics Ltd.engages in research and development of biotechnology. The company was founded on March 29, 2019 and is headquartered in in Reading, the United Kingdom. | Biotechnology | Director/Board Member | |
Epidarex Capital Partners LLC
Epidarex Capital Partners LLC Investment ManagersFinance Epidarex Capital Partners LLC (Epidarex Capital) is a venture capital firm founded in 2010 by Kyparissia Sirinakisvin. The firm is headquartered in Bethesda, Maryland. | Investment Managers | Private Equity Analyst | |
NodThera Ltd.
NodThera Ltd. BiotechnologyHealth Technology NodThera Ltd. researches and develops novel inhibitors of the NLRP3 inflammasome. The company is headquartered in Little Chesterford, the United Kingdom. | Biotechnology | Corporate Officer/Principal |
Statistieken
Internationaal
Verenigd Koninkrijk | 21 |
Verenigde Staten | 11 |
Duitsland | 4 |
Italië | 2 |
Israël | 2 |
Sectoraal
Health Technology | 14 |
Finance | 10 |
Consumer Services | 8 |
Commercial Services | 8 |
Health Services | 2 |
Operationeel
Director/Board Member | 17 |
Corporate Officer/Principal | 9 |
Private Equity Investor | 9 |
Chief Tech/Sci/R&D Officer | 7 |
Graduate Degree | 3 |
Sterkste connecties
- Beurs
- Insiders
- Jan Thirkettle
- Bedrijfsconnecties